CreosG Completes US FDA Phase 1... MOU for Joint Research Based on 'Anti-Aging' Substance

CreoSG announced on the 18th that it has signed a strategic business agreement (MOU) with the natural products specialist company ‘Hepatol’ to conduct various research and development (R&D) based on the ‘Cell Activation Factor (CAF).’ CAF is a natural substance with anti-aging effects, which has already successfully completed Phase 1 clinical trials in the United States as a new drug and has been validated for efficacy by being registered as an NFI (Novel Food Ingredient) medical food in Europe.

This MOU focuses on the joint research between the two companies to apply Hepatol’s CAF-related technology to CreoSG’s proprietary vaccine development platform ‘SUV-MAP’ for ▲ development of immuno-oncology drugs ▲ maximizing the delivery efficiency of CAF in the body ▲ and studying the mechanism of action of CAF. CreoSG plans to conduct joint research with Hepatol based on its accumulated R&D capabilities and vector (delivery system) technology from various vaccine development processes.

CAF, a natural substance extracted from marine brown algae, stimulates mitochondria within cells to remove fat and generate muscle, making it effective for treating metabolic diseases. The company explained that CAF-based new drugs not only normalize cells affected by various aging factors but also selectively eliminate pathological cells.

CAF has already completed efficacy and safety verification in the global market. Phloronol, a U.S. biotech company affiliated with Hepatol, received IND (Investigational New Drug) approval from the U.S. Food and Drug Administration (FDA) for CAF-based anti-aging treatments and completed Phase 1 clinical trials in the U.S. In South Korea, Phase 2a clinical trials have been completed, and Phase 2b trials are being prepared. Hepatol has obtained safety certification for medical foods used to treat non-alcoholic fatty liver disease and pancreatic conditions in the U.S. and Europe, secured sales authorization in 26 European countries, and is currently selling in six countries including the United Kingdom and France.

A CreoSG official stated, “We signed this MOU because our proprietary platform SUV-MAP’s technology and R&D capabilities in vaccines and immuno-oncology drugs were highly evaluated,” adding, “We plan to collaborate with Hepatol, a company possessing CAF technology recognized as a next-generation anti-aging substance, to develop various new drugs and pharmaceuticals.”

He continued, “Through multiple experiments, CAF has been confirmed to not only prevent muscle loss in the elderly but also increase muscle generation regardless of age, showing musculoskeletal improvement effects,” adding, “Based on its outstanding performance, we will maximize the delivery effect of CAF as an anti-aging treatment and expand its application fields through multifaceted cooperation, aiming to enter domestic and international markets starting next year.”